wherein each R is selected from the group consisting of hydrogen and alkali metal; each R1, R2 and R3 is selected from the group consisting of hydrogen and SO3A, wherein A is selected from the group consisting of hydrogen and a pharmaceutically acceptable salt cation; provided that at least one of the R1, R2 and R3 groups on each phenyl is SO3A; and further provided that when R2 is SO3A. R1 and R, may not be SO3A. E.g., these compounds may be prepared according to the following flowchart:wherein R' stands forThese compounds find utility as complement inhibitors in body fluids and as such may be used to ameliorate or prevent those pathological reactions requiring the function of complement and in the therapeutic treatment of warm-blooded animals having immunologic diseases."/> Symm. phenyltris(sulfonylimino)tri-benzene sulfonic acids and salts, a method of inhibiting the complement system in a body fluid with such a compound, a method for the preparation of such compounds and a pharmaceutical composition comprising such a compound
首页> 外国专利> Symm. phenyltris(sulfonylimino)tri-benzene sulfonic acids and salts, a method of inhibiting the complement system in a body fluid with such a compound, a method for the preparation of such compounds and a pharmaceutical composition comprising such a compound

Symm. phenyltris(sulfonylimino)tri-benzene sulfonic acids and salts, a method of inhibiting the complement system in a body fluid with such a compound, a method for the preparation of such compounds and a pharmaceutical composition comprising such a compound

机译:象征苯基三(磺酰氨基)三苯磺酸和盐,用这种化合物抑制体液中补体系统的方法,制备这种化合物的方法和包含该化合物的药物组合物

摘要

There are provided s-phenyltris (sulfonylimino) tri- benzene mono- and di-sulfonic acids and their salts which are useful as complement inhibitors. The novel compounds have the general formula:wherein each R is selected from the group consisting of hydrogen and alkali metal; each R1, R2 and R3 is selected from the group consisting of hydrogen and SO3A, wherein A is selected from the group consisting of hydrogen and a pharmaceutically acceptable salt cation; provided that at least one of the R1, R2 and R3 groups on each phenyl is SO3A; and further provided that when R2 is SO3A. R1 and R, may not be SO3A. E.g., these compounds may be prepared according to the following flowchart:wherein R' stands forThese compounds find utility as complement inhibitors in body fluids and as such may be used to ameliorate or prevent those pathological reactions requiring the function of complement and in the therapeutic treatment of warm-blooded animals having immunologic diseases.
机译:提供了可用作补体抑制剂的s-苯基三(磺酰亚胺)三苯单磺酸和二磺酸及其盐。新化合物的通式为: <图像文件=“ IMGA0001.GIF” he =“ 21” imgContent =“ chem” imgFormat =“ GIF” inline =“ no” wi =“ 52” /> 其中每个R选自氢和碱金属;每个R 1 ,R 2 和R 3 选自氢和SO 3 A,其中A选自氢和药学上可接受的盐阳离子;条件是每个苯基上的R 1 ,R 2 和R 3 中的至少一个是SO 3 一种;并进一步规定,当R 2 是SO 3 A时。 R 1 和R,可能不是SO 3 A。例如,可以根据以下流程图制备这些化合物: <图像文件=“ IMGA0002.GIF” he =“ 38” imgContent =“ chem” imgFormat =“ GIF” inline =“ no” wi =“ 80” /> 其中R ' 代表 <图像文件=“ IMGA0003.GIF” he =“ 6” imgContent =“ chem” imgFormat =“ GIF” inline =“ no” wi =“ 34” /> 这些化合物可以在体液中用作补体抑制剂,因此可以用于改善或预防那些需要补体功能的病理反应,并可以治疗患有免疫性疾病的温血动物。

著录项

  • 公开/公告号EP0013079A1

    专利类型

  • 公开/公告日1980-07-09

    原文格式PDF

  • 申请/专利权人 AMERICAN CYANAMID COMPANY;

    申请/专利号EP19790302684

  • 发明设计人 CONROW RANSOM B.;BERNSTEIN SEYMOUR;

    申请日1979-11-23

  • 分类号C07C143/78;A61K31/185;

  • 国家 EP

  • 入库时间 2022-08-22 17:56:57

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号